These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6025965)

  • 21. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD; Cooper B; Rufo RR; Nienhuis AW; Anderson WF; Bunn HF; Rosenthal A; Nathan DG
    N Engl J Med; 1977 Aug; 297(8):418-23. PubMed ID: 882111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of hypersiderosis with Desferal].
    Anatkov A; Gekova K
    Vutr Boles; 1972; 11(6):56-9. PubMed ID: 4680042
    [No Abstract]   [Full Text] [Related]  

  • 24. [A new iron chelating agent: desferrioxamine B (Desferal). Clinico-pharmacological observations. Cases].
    Gallinelli R; Coppini D
    Minerva Med; 1965 Nov; 56(92):3980-5. PubMed ID: 5845686
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of desferrioxamine-induced sideruria and measurement of labile iron store as indices of body iron status.
    Singh AK
    J Med; 1971; 2(6):345-62. PubMed ID: 5292126
    [No Abstract]   [Full Text] [Related]  

  • 26. Urinary iron excretion in patients with prosthetic heart valves.
    Walsh JR; Brodeur MT; Ritzmann LW; Sutherland DW; Starr A
    JAMA; 1966 Oct; 198(5):505-10. PubMed ID: 5953308
    [No Abstract]   [Full Text] [Related]  

  • 27. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 28. [Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)].
    de Montalembert M; Jan D; Clairicia M; Hannedouche T; Sidi D; Girot R
    Arch Fr Pediatr; 1992 Mar; 49(3):159-63. PubMed ID: 1610270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Desferrioxamine in thalassemia].
    Biener R; Freundlich E; Rachmilewitz E
    Harefuah; 1983 May; 104(10):438-40. PubMed ID: 6629159
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 32. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
    Kobayashi M; Yano K; Fujisawa S
    Rinsho Ketsueki; 1996 Apr; 37(4):303-10. PubMed ID: 8847800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of primary idiopathic hemochromatosis and secondary hemosiderosis].
    Strohmeyer G
    Dtsch Med Wochenschr; 1974 Nov; 99(45):2295-9. PubMed ID: 4448138
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of desferal and some data on hemosiderosis in hypo- and aplastic anemias].
    Fainshtein FE; Trubina NS; Sobaleva IuG; Rozanova NS; Voronina AN
    Probl Gematol Pereliv Krovi; 1968 Aug; 13(8):31-8. PubMed ID: 5736846
    [No Abstract]   [Full Text] [Related]  

  • 35. [Subcutaneous administration of deferoxamine in a patient with panmyelopathy and post-transfusion hemosiderosis].
    Zdziarska B; Urasiński I
    Pol Arch Med Wewn; 1987 Jul; 78(1):48-51. PubMed ID: 3271285
    [No Abstract]   [Full Text] [Related]  

  • 36. [Post-transfusion hemochromatosis. Results of a study carried out in Blood Transfusion Centers. Analysis of 15 cases treated with subcutaneous perfusion of Desferal. Working group "Transfusion Techniques and Therapeutics"].
    Jaulmes D; Quarre MC; Audat F; Gaonach MJ
    Transfus Clin Biol; 1994; 1(1):55-64. PubMed ID: 8186855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy of hemosiderosis with deferoxamine].
    Strohmeyer G; Stremmel W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1669-70. PubMed ID: 6489179
    [No Abstract]   [Full Text] [Related]  

  • 38. Current concepts in the overall management of thalassemia.
    Propper RD
    Ann N Y Acad Sci; 1980; 344():375-83. PubMed ID: 6930877
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
    Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
    [No Abstract]   [Full Text] [Related]  

  • 40. Chelation therapy for iron overload.
    Nutr Rev; 1980 May; 38(5):185-7. PubMed ID: 7207885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.